cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bio Techne Corp
1 own
9 watching
Current Price
$80.32
$0.49
(0.61%)
logo-tech
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
12,604.49M
52-Week High
52-Week High
113.805
52-Week Low
52-Week Low
68.0025
Average Volume
Average Volume
0.8M
Dividend Yield
Dividend Yield
0.002574
P/E Ratio
P/E Ratio
143.3873
iconMarket Capitalization12,604.49M
icon52-Week High113.805
icon52-Week Low68.0025
iconAverage Volume0.8M
iconDividend Yield0.002574
iconP/E Ratio143.3873
What does the Bio Techne Corp do?
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company operates through three segments: Biotechnology, Clinical Controls, and Protein Platforms. The Biotechnology segment provides proteins, such as cytokines, growth factors, and enzymes; polyclonal antibodies in goats, sheep, and rabbits, as well as monoclonal antibodies; microtiter-plate based kits, immunoassays based on encoded bead technology and planar spotted surfaces, and microfluidic-based immunoassays to quantify the level of a specific protein in biological fluids; and erythropoietin, transferrin receptor, and Beta2-microglobulin immunoassays for use as in vitro diagnostic devices. This segment also offers fluorochrome labeled antibodies and kits to determine the immuno-phenotypic properties of cells from various tissues; and natural or synthetic chemical compounds for use as agonists, antagonists, and/or inhibitors of various biological functions. The Clinical Controls segment provides hematology controls and calibrators for hematology clinical instruments; clinical controls for blood glucose and blood gas devices, as well as coagulation device control products; and bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry. The Protein Platforms segment develops, manufactures, and sells tools comprising Simple Western platform, an assay for protein analysis and identification; SimplePlex platform, an assay used in research and clinical diagnostics; and Biologics Instrumentation to interrogate protein purity and identify contaminants during the development and production of biologics. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Read More
How much money does Bio Techne Corp make?
News & Events about Bio Techne Corp.
PR Newswire
11hours ago
BIO-TECHNE LAUNCHES THE MauriceFlex SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS BIO-TECHNE LAUNCHES THE MauriceFlex SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS PR Newswire MINNEAPOLIS, Jan. 26, 2023 MINNEAPOLIS, Jan. 26, 2023...
PR Newswire
1month ago
BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire MINNEAPOLIS, Dec. 21, 2022 MINNEAPOLIS, Dec. 21, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck...
PR Newswire
1month ago
BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE PR Newswire MINNEAPOLIS, Nov. 28, 2022 MINNEAPOLIS, Nov. 28, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that...
Zolmax
3 months ago
ProShare Advisors LLC trimmed its position in shares of Bio-Techne Co. (NASDAQ:TECH Get Rating) by 28.4% in the second quarter, Holdings Channel.com reports. The firm owned 5,947 shares of the biotechnology companys stock after selling 2,357 shares during the period. ProShare Advisors LLCs holdings ...
PR Newswire
3 months ago
BIO-TECHNE TO HOST CONFERENCE CALL ON NOVEMBER 1, 2022, TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS BIO-TECHNE TO HOST CONFERENCE CALL ON NOVEMBER 1, 2022, TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS PR Newswire MINNEAPOLIS, Oct. 10, 2022 MINNEAPOLIS, Oct. 10, 2022 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Bio Techne Corp share price today?
plus_minus_icon
Can Indians buy Bio Techne Corp shares?
plus_minus_icon
How can I buy Bio Techne Corp shares from India?
plus_minus_icon
Can Fractional shares of Bio Techne Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Bio Techne Corp stocks?
plus_minus_icon
What is today’s traded volume of Bio Techne Corp?
plus_minus_icon
What is today’s market capitalisation of Bio Techne Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Bio Techne Corp?
plus_minus_icon
What percentage is Bio Techne Corp down from its 52-Week High?
plus_minus_icon
What percentage is Bio Techne Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$80.32
$0.49
(0.61%)
logo-tech
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00